Genetic Variations Appear To Be Vital Markers For Cervical Cancer Progression

Patients having particular alterations in the cancer genome are at 3-4 times higher risk of recurrence subsequent to the standard cervical cancer treatment when evaluated against those patients that did not have such alterations. This was part of the study conducted by Norwegian researchers and has been printed in the 13th November edition in the open-access academic journal ‘PLoS Genetics’. The research indicates that particular genetic variations are decisive stages revealing that the disease is progressing to a more belligerent and treatment-immune phase.

Cervical cancer is one of the most prevalent forms of cancer that affects women globally and a key reason behind cancer-linked fatalities. Hence, the researchers have endeavoured to investigate if these genetic alterations could provide additional information to the clinical data derived from standard assessment means, and be employed for identifying patients that require further treatment. Past studies have revealed that there were several genetic variations in the cancer cells of those affected with cervical cancer; however their significance in the disease proliferation and treatment immunity is yet to be thoroughly delved.

Heidi Lyng, head author of the study observed more than 140 patients who had been detected with cervical cancer and underwent treatment at the Norwegian Radium Hospital. Employing screening techniques covering all genes in the human genome, the researchers cited that their main discovery was the collection of biological processes which are found to be the traits of cancer related to the growth and pasting of particular genes. Furthermore, they detected new loci related to immunity against chemotherapy and radiotherapy, and illustrated the genes entailed in this process.

This research signifies a significant move in deciphering how cervical cancer develops, however the authors accentuated the fact that the outcomes need to be authenticated in independent patient groups prior to considering their usage in clinical decision-making.

Popularity: 2% [?]